2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162526
    HIV capsid modulator 2 98%
    HIV capsid modulator 2 (Compound 7t) is a modulator for the HIV capsid (CA) protein. HIV capsid modulator 2 exhibits antiviral activity, which inhibits HIV-1 IIIB strain and HIV-2 ROD strain with EC50 of 0.04 and 0.13 μM. HIV capsid modulator 2 is metabolically stable in human liver microsomes.
    HIV capsid modulator 2
  • HY-162527
    Antibacterial agent 216 98%
    Antibacterial agent 216 (Compound 2a) is an antibacterial agent that exhibits significant bactericidal effects when combined with INH and RIF. Antibacterial agent 216 has demonstrated remarkable in vitro anti-tuberculosis activity against Mtb H37Rv and MDR clinical isolates and can be used for tuberculosis research.
    Antibacterial agent 216
  • HY-162564
    Antibacterial agent 221 3034402-33-7 98%
    Antibacterial agent 221 (compound 3k) is a potent inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 221 shows significant cytotoxicity against human LO2 and HepG2 cells.
    Antibacterial agent 221
  • HY-162595
    BDM88855 2892824-25-6 98%
    BDM88855 is an allosteric inhibitor for the homolog AcrB protein. BDM88855 can boost the antibacterial effect of a panel of antibiotics (eg: Oxacillin (HY-B0925A), Linezolid (HY-10394), Novobiocin (HY-B0425), etc.) on wild-type E. coli.
    BDM88855
  • HY-162599
    Spirohypertone B 98%
    Spirohypertone B is a potent Tumor necrosis factor-α (TNF-α) inhibitor. Spirohypertone B protects L929 cells from death induced by co-incubation with TNF-α and Actinomycin D (HY-17559).
    Spirohypertone B
  • HY-162648
    Succinate dehydrogenase-IN-1 2969128-94-5 98%
    Succinate dehydrogenase-IN-1 (Compound 34) is an inhibitor for succinate dehydrogenase (SDH) with an IC50 of 0.94 μM and a KD of 22.4 μM. Succinate dehydrogenase-IN-1 exhibits antifungal activity against Rhizoctonia solani, Sclerotinia sclerotiorum, Monilinia fructicola, and Botrytis cinerea, with EC50 of 0.04 μM, 1.13 μM, 1.61 μM and 1.21 μM, respectively.
    Succinate dehydrogenase-IN-1
  • HY-162680
    OSC-GCDI(P) 98%
    OSC-GCDI(P) is a broad-spectrum orally active anti-influenza virus agent that exhibits significant inhibitory effects against both wild-type and Oseltamivir (HY-13317) resistant (H275Y) influenza virus strains in mouse infection models. OSC-GCDI(P) is capable of preventing not only wild-type influenza viruses but also OS-resistant variants with NA(H275Y).
    OSC-GCDI(P)
  • HY-162684
    Antitubercular agent-46 98%
    Antitubercular agent-46 (4B) is an anti-tubercular agent, with a MIC of 7.81 μg/ mL. Antitubercular agent-46 (4B) possesses antioxidant activity.
    Antitubercular agent-46
  • HY-162687
    Antibacterial agent 232 2694805-94-0 98%
    Antibacterial agent 232 (compound Y41) is a potent antibacterial agent. Antibacterial agent 232 disrupts the cell membrane integrity by inducing cell peroxidation.
    Antibacterial agent 232
  • HY-162696
    mCMQ069 3025257-02-4 98%
    mCMQ069 is an orally active and potent antimalarial. mCMQ069 has potential for a single-dose cure and/or 28-day chemoprevention.
    mCMQ069
  • HY-162701
    Antiviral agent 58 939655-35-3 98%
    Antiviral agent 58 (Compound J1) is an orally active antiviral agent with broad-spectrum antiviral activity against enveloped viruses, including influenza A virus (IAV), respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human coronavirus OC43 (HCoV-OC43), herpes simplex virus type 1 (HSV-1), and HSV-2.
    Antiviral agent 58
  • HY-162715
    EV-A71-IN-2 98%
    EV-A71-IN-2 (compound 6c) is a anti-EV-A71 agent with the EC50 values of 0.29 μM and 1.66 μM aganist of EV-A71-MRC-5 cells and EV-A71-RD cells, respectively. EV-A71-IN-2 can be used for study of enterovirus infection.
    EV-A71-IN-2
  • HY-162720
    NNRT-IN-4 98%
    NNRT-IN-4 (Compound 10p) is an inhibitor for non-nucleoside reverse transcriptase (NNRT) with an IC50 of 0.713 µM for HIV-1 RT. NNRT-IN-4 exhibits antiviral efficacy, inhibits HIV-1 wildtype and mutant strains with EC50 of 6-63 nM. NNRT-IN-4 exhibits a slight inhibitory activities against hERG (IC50=25.9 µM) and CYP enzymes (IC50>50 µM). NNRT-IN-4 exhibits good tolerability and safety in mice (2 g/kg).
    NNRT-IN-4
  • HY-162725
    TLR7 agonist 24 98%
    TLR7 agonist 24 (Compound 21) is an agonist for TLR7 with EC50 of 3.72 μM. TLR7 agonist 24 can be used as a vaccine adjuvant when combined with Aluminum Hydroxide (HY-B1521), that enhances the immune response against SARS-CoV-2 and hepatitis B antigens.
    TLR7 agonist 24
  • HY-162775
    TST1N-224 50566-97-7 98%
    TST1N-224 is a potent response regulator VraRC inhibitor. TST1N-224 can disrupt VraRC-DNA complex formation (IC50=60.2 μM). TST1N-224 exhibits interference with VraRC binding to its cognate DNA through a fast-on-fast-off binding mechanism (KD=23.4 μM). TST1N-224 predominantly interacts with the α9- and α10-helixes of the DNA-binding domain of VraR. TST1N-224 inhibits the growths of S. aureus (SA; MIC>126 μM), Methicillin-resistant S. aureus (MRSA; MIC>126 μM), and Vancomycin-intermediate S. aureus (VISA; MIC=63 μM). TST1N-224, an antimicrobial agent, evidently enhances the susceptibility of VISA to both Vancomycin (HY-B0671) and Methicillin (HY-B0974).
    TST1N-224
  • HY-162776
    Succinate dehydrogenase-IN-3 98%
    Succinate dehydrogenase-IN-3 (Ig) is an inhibitor of Succinate dehydrogenase (SDH). Succinate dehydrogenase-IN-3 has antifungal activity.
    Succinate dehydrogenase-IN-3
  • HY-162777
    SARS-CoV-2-IN-93 98%
    SARS-CoV-2-IN-93 (compound 24) is an inhibitor of SARS-CoV-2 and HCoV-OC43. SARS-CoV-2-IN-93 can be used in antiviral research.
    SARS-CoV-2-IN-93
  • HY-162778
    FM-1088 2410561-64-5 98%
    FM-1088 is an insecticide. FM-1088 can be used in research related to crop disease and insect pest control.
    FM-1088
  • HY-162784
    CYP51-IN-19 3006888-90-7 98%
    CYP51-IN-19 (compound C07) is a potent CYP51 inhibitor. CYP51-IN-19 stimulates reactive oxygen species (ROS) and exhibits potent fungicidal activity.
    CYP51-IN-19
  • HY-162785
    XC219 98%
    XC219 (compound 43) is a cyclin-dependent kinase CDK) inhibitor, that covalently binds to CDK active site Lys. XC219 can be used in antifungal research.
    XC219
Cat. No. Product Name / Synonyms Application Reactivity